(Q51514655)

6 April 2018

title

A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. (English)

1 reference

6 April 2018

1 reference

1 reference

M Wadelius

4

0 references

Munir Pirmohamed

object named as

M Pirmohamed

5

0 references

author name string

P J Avery

1

1 reference

6 April 2018

A Jorgensen

2

1 reference

6 April 2018

A K Hamberg

3

1 reference

6 April 2018

F Kamali

6

1 reference

6 April 2018

EU-PACT Study Group

7

1 reference

6 April 2018

language of work or name

English

0 references

publication date

28 September 2011

1 reference

6 April 2018

Clinical Pharmacology & Therapeutics

published in

1 reference

6 April 2018

volume

90

1 reference

6 April 2018

issue

5

1 reference

6 April 2018

page(s)

701-706

1 reference

6 April 2018

Pharmacogenetics of warfarin

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.186

Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.186

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.186

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.186

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.186

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.186

A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.186

Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.186

21 January 2018

Identifiers

DOI

10.1038/CLPT.2011.186

1 reference

6 April 2018

1 reference

6 April 2018